Life Sciences Drug DevelopmentBoston, MA
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis. The Company has developed deep insights into the connection between the individual components of these systems and the resulting role in many chronic diseases, which have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative therapies across two divisions: the Affiliates division (inclusive of deconsolidated affiliates) and the Internal division. Its Affiliates division includes two product candidates that have been filed with the U.S. Food and Drug Administration (FDA) for review and several other novel clinical and pre-clinical programs. These affiliates are developing highly innovative platforms and therapeutic candidates in collaboration with some of the world’s leading scientific experts.
PureTech’s Internal division is advancing a pipeline fueled by recent discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. These programs leverage the transport and biodistribution of various immune system components for the targeted treatment of diseases with major unmet needs, including cancers, autoimmune and neuroimmune disorders.